Edgar Filing: TETRAPHASE PHARMACEUTICALS INC - Form 4

TETRAPHAS Form 4 June 11, 2015	E PHARMAC	EUTICAI	LS INC							
FORM Check this	N OMB Number:	PROVAL 3235-0287								
if no longer subject to Section 16. Form 4 or Form 5 obligations may contin <i>See</i> Instruc 1(b).	Filed pur Filed pur ue. Section 17(STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Expires: January Expires: Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 Expires: January Expires:								
1. Name and Address of Reporting Person * 2. Issuer BOHLIN GAREN G Symbol TETRAI PHARM (Last) (First) (Middle) 3. Date of (Month/Date) (Month/Date)			TETRAPHASE PHARMACEUTICALS INC		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
			. Date of Earliest TransactionOfficer Month/Day/Year) 6/10/2015			give title Other (specify below)				
(Street) WATERTOWN, MA 02472			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)	Tab	le I - Non-De	rivative Securities A	cquired, Disposed	of, or Beneficia	lly Owned		
	. Transaction Date Month/Day/Year)		Date, if	TransactionA Code D	Securities cquired (A) or isposed of (D) nstr. 3, 4 and 5) (A) or .mount (D) Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Repor	rt on a separate lind	e for each cl	ass of sec	urities benefic.	information cont required to respo	or indirectly. spond to the colle ained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)		
	Tab	le II - Deriv	vative Sec	urities Acqui	red, Disposed of, or	Beneficially Owned	d			

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amoun	t of 8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securit	ies D

Edgar Filing: TETRAPHASE PHARMACEUTICALS INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired or Dispose (D) (Instr. 3, 4 and 5)	(A) ed of	(Month/Day/Year)		(Instr. 3 and 4)		(
				Code N	/ (A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	,
Stock option (right to buy)	\$ 42.26	06/10/2015		А	10,000		<u>(1)</u>	06/09/2025	Common Stock	10,000	

Reporting Owners

Reporting Owner Name / Address				
i O	Director	10% Owner	Officer	Other
BOHLIN GAREN G 480 ARSENAL ST. SUITE 110 WATERTOWN, MA 02472	Х			
Signatures				
/s/ Maria Stahl, as Attorney-in-Fa Bohlin	ren	06/1	1/2015	
<u>**</u> Signature of Reporting Pers		Γ	Date	
Explanation of Poo	none	001		

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Vests in equal quarterly installments over a one-year period measured from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

S ()